Key facts
- This page summarizes Amy E. Tapper's Form 4 filing for Imago BioSciences, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Jan 2022, 17:47.
Amy E. Tapper - 12 Jan 2022 Form 4 Insider Report for Imago BioSciences, Inc.
- Reporting relationship
- Senior Vice President, Non-Clinical and CMC
- Issuer ticker
- N/A
- Reported as of
- 12 Jan 2022
- Net transaction value
- -$110,630
- SEC form
- 4
- Accepted by SEC
- 14 Jan 2022, 17:47:36 UTC
- Prior SEC filing
- 19 Nov 2021
- Next SEC filing
- 03 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Hugh Rienhoff, as Attorney-in-fact for Amy Tapper
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amy E. Tapper filed Form 4 for Imago BioSciences, Inc. on 14 Jan 2022.
Change
- Previous filing in this sequence was filed on 19 Nov 2021.
- Current net transaction value: -$110,630.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMGO
transaction
Common Stock
Options Exercise
- Transaction value
- $9,120
- Shares
- +6,000
- Change %
- +5%
- Price
- $1.52*
- Shares after
- 125,047
- Date
- 12 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
IMGO
transaction
Common Stock
Sale
- Transaction value
- $119,750
- Shares
- -6,000
- Change %
- -4.8%
- Price
- $19.96
- Shares after
- 119,047
- Date
- 12 Jan 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMGO
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -6,000
- Change %
- -18%
- Price
- $0.000000
- Shares after
- 26,738
- Date
- 12 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,000
- Exercise price
- $1.52
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
Footnote F2
The transaction was executed in multiple trades in prices ranging from $19.68 to $20.24, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F3
One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
SEC remarks
Senior Vice President, Non-Clinical and CMC